WP
PRTK

WealthShield Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

WealthShield Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,500
Closed -$18K – 1205
2021
Q1 		$18K Buy
+2,500
New +$18K ﹤0.01% 690

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthShield Partners's PRTK Position: Q2 2021 in Review

WealthShield Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2021, closing a stake of 2,500 shares — an estimated $18K sold.

WealthShield Partners first reported a position in PRTK in Q1 2021 and held it in 1 quarter. The position peaked at $18K in Q1 2021. 116 funds tracked by Wall St. Rank hold PRTK as of Q2 2021.

  • WealthShield Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • WealthShield Partners sold 2,500 Paratek Pharmaceuticals, Inc. shares in Q2 2021, an estimated $18K.
  • WealthShield Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • WealthShield Partners's Paratek Pharmaceuticals, Inc. position peaked at $18K in Q1 2021.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.